User profiles for Ivan Marquez-Rodas
 | IVAN MARQUEZ RODAS (ORCID: 0000-0002-2476-668X)Instituto de Investigación Sanitaria Gregorio Marañón Verified email at salud.madrid.org Cited by 25272 |
[HTML][HTML] Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
…, D Hogg, A Hill, I Márquez-Rodas… - New England journal …, 2019 - Mass Medical Soc
Background Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free
and overall survival than ipilimumab alone in a trial involving patients with advanced …
and overall survival than ipilimumab alone in a trial involving patients with advanced …
[HTML][HTML] Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
…, MO Butler, A Hill, I Márquez-Rodas… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
… Ivan Márquez-Rodas … Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard
Dummer, Pier Francesco Ferrucci, Andrew Hill, Ivan Márquez-Rodas, John BAG Haanen …
Dummer, Pier Francesco Ferrucci, Andrew Hill, Ivan Márquez-Rodas, John BAG Haanen …
[HTML][HTML] Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
…, JB Haanen, M Maio, I Marquez-Rodas… - New England journal …, 2015 - Mass Medical Soc
Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been …
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been …
[HTML][HTML] Overall survival with combined nivolumab and ipilimumab in advanced melanoma
…, O Bechter, M Maio, I Marquez-Rodas… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab combined with ipilimumab resulted in longer progression-free survival
and a higher objective response rate than ipilimumab alone in a phase 3 trial involving …
and a higher objective response rate than ipilimumab alone in a phase 3 trial involving …
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
…, SJ Moschos, D Hogg, I Márquez-Rodas… - The Lancet …, 2017 - thelancet.com
Background Dabrafenib plus trametinib improves clinical outcomes in BRAF V600 -mutant
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
…, V Chiarion-Sileni, I Marquez-Rodas… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised …
…, M Smylie, A Hill, D Hogg, I Marquez-Rodas… - The Lancet …, 2018 - thelancet.com
Background Previously reported results from the phase 3 CheckMate 067 trial showed a
significant improvement in objective responses, progression-free survival, and overall survival …
significant improvement in objective responses, progression-free survival, and overall survival …
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised …
…, JJ Grob, V Chiarion-Sileni, I Márquez-Rodas… - The Lancet …, 2020 - thelancet.com
Background Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant
trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant …
trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant …
[HTML][HTML] Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
…, WH Miller Jr, P Mohr, I Marquez-Rodas… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional
therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint …
therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint …
Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death …
…, A Berrocal, I Márquez-Rodas… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of
programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP…
programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP…
